New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)

.

Bibliographic Details
Main Author: Article Editorial
Format: Article
Language:English
Published: Столичная издательская компания 2016-09-01
Series:Рациональная фармакотерапия в кардиологии
Online Access:https://www.rpcardio.com/jour/article/view/1319
_version_ 1797659285438595072
author Article Editorial
author_facet Article Editorial
author_sort Article Editorial
collection DOAJ
description .
first_indexed 2024-03-11T18:12:48Z
format Article
id doaj.art-fcfd611199814f7c909a4a9aaf338e89
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-11T18:12:48Z
publishDate 2016-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-fcfd611199814f7c909a4a9aaf338e892023-10-16T11:32:10ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-09-011244874881252New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)Article Editorial.https://www.rpcardio.com/jour/article/view/1319
spellingShingle Article Editorial
New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
Рациональная фармакотерапия в кардиологии
title New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
title_full New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
title_fullStr New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
title_full_unstemmed New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
title_short New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
title_sort new data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug xarelto r in patients with atrial fibrillation press release of the company bayer
url https://www.rpcardio.com/jour/article/view/1319
work_keys_str_mv AT articleeditorial newdatafromclinicalpracticeagainconfirmedthehighefficacyandafavorablesafetyprofileofthedrugxareltoinpatientswithatrialfibrillationpressreleaseofthecompanybayer